• Biopharma generally outperforms other sectors, even other healthcare sectors, in a recession.
• But, some drug classes fare better than others. Resilient branded drug classes tend to be highly effective, treat severe and/or acute diseases, and face little competitive pressure.
• For those drug classes that address less severe diseases or face low-cost alternatives, drug makers need to work to ensure continued access and adherence.